The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-27
DOI
10.1186/s13045-019-0808-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
- (2018) Oliver G. Ottmann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
- (2018) Ulrike Tontsch-Grunt et al. CANCER LETTERS
- Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?
- (2018) Manuel Haschka et al. EMBO REPORTS
- Aneuploidy: Cancer strength or vulnerability?
- (2018) Giorgia Simonetti et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
- (2018) Jiayi Yu et al. Journal of Hematology & Oncology
- Chromothripsis in acute myeloid leukemia: biological features and impact on survival
- (2018) Maria Chiara Fontana et al. LEUKEMIA
- A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
- (2018) Shyamala C. Navada et al. LEUKEMIA RESEARCH
- Clinically Applicable Inhibitors Impacting Genome Stability
- (2018) Anu Prakash et al. MOLECULES
- Abstract 1885: Selective Polo-like Kinase 1 (PLK1) inhibitor PCM-075 is highly active alone and shows synergy when combined with FLT3 inhibitors in models of acute myeloid leukemia (AML)
- (2018) Karena Kosco et al. CANCER RESEARCH
- Chromosome integrity checkpoints in stem and progenitor cells: transitions upon differentiation, pathogenesis, and aging
- (2018) Andreas Brown et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Autophagy Governs Protumorigenic Effects of Mitotic Slippage–induced Senescence
- (2018) Rekha Jakhar et al. MOLECULAR CANCER RESEARCH
- Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes
- (2018) Marc Payton et al. MOLECULAR CANCER THERAPEUTICS
- Nuclear envelope assembly defects link mitotic errors to chromothripsis
- (2018) Shiwei Liu et al. NATURE
- CFI-400945 is not a selective cellular PLK4 inhibitor
- (2018) Karen Oegema et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Consequences of mitotic slippage for antimicrotubule drug therapy
- (2017) Bing Cheng et al. ENDOCRINE-RELATED CANCER
- Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
- (2017) Frank G. Rücker et al. HAEMATOLOGICA
- Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis
- (2017) M Ratnaparkhe et al. LEUKEMIA
- Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
- (2017) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic antileukemic therapies inNOTCH1-induced T-ALL
- (2017) Marta Sanchez-Martin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potential therapeutic targets and small molecular drugs for pediatric B-precursor acute lymphoblastic leukemia treatment based on microarray data
- (2017) Limei Kong et al. Oncology Letters
- Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
- (2017) Yoshiya Adachi et al. Oncotarget
- Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
- (2017) Dominik Schnerch et al. Oncotarget
- CDK1 and PLK1 coordinate the disassembly and reassembly of the nuclear envelope in vertebrate mitosis
- (2017) Ines J de Castro et al. Oncotarget
- Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A
- (2017) Karine Z. Oben et al. Oncotarget
- Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
- (2017) Frank G. Rücker et al. HAEMATOLOGICA
- Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent–induced mitotic arrest
- (2017) Yasuo Tsuda et al. Scientific Reports
- Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia
- (2016) Samad Ghanizadeh-Vesali et al. ANNALS OF HEMATOLOGY
- Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
- (2016) Si-Jia He et al. CANCER LETTERS
- Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- (2016) A. Kothari et al. CANCER RESEARCH
- Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression
- (2016) Shuichiro Okamoto et al. CANCER SCIENCE
- NUP98 fusion oncoproteins interact with the APC/CCdc20as a pseudosubstrate and prevent mitotic checkpoint complex binding
- (2016) Valentina Salsi et al. CELL CYCLE
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
- (2016) Karen W. L. Yee et al. INVESTIGATIONAL NEW DRUGS
- Positive Feedback Keeps Duration of Mitosis Temporally Insulated from Upstream Cell-Cycle Events
- (2016) Ana Rita Araujo et al. MOLECULAR CELL
- Alisertib induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells
- (2016) YUNFENG FU et al. Molecular Medicine Reports
- A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
- (2016) B. Vormoor et al. PEDIATRIC BLOOD & CANCER
- Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia
- (2016) Daniel Ewerth et al. Oncotarget
- Prolonged mitotic arrest induces a caspase-dependent DNA damage response at telomeres that determines cell survival
- (2016) Karolina O. Hain et al. Scientific Reports
- Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
- (2016) Amir T. Fathi et al. HAEMATOLOGICA
- Cell Division Cycle 6 Promotes Mitotic Slippage and Contributes to Drug Resistance in Paclitaxel-Treated Cancer Cells
- (2016) Yue He et al. PLoS One
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
- (2015) Yukio Kobayashi et al. CANCER SCIENCE
- Entry into mitosis: a solution to the decades-long enigma of MPF
- (2015) Takeo Kishimoto CHROMOSOMA
- Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
- (2015) Daniel J. DeAngelo et al. Clinical Lymphoma Myeloma & Leukemia
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Chromothripsis in cancer cells: An update
- (2015) Agata Rode et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Cdc20 as a novel cancer therapeutic strategy
- (2015) Lixia Wang et al. PHARMACOLOGY & THERAPEUTICS
- G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound
- (2015) Maia Cabrera et al. PLoS One
- Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function
- (2015) Job de Lange et al. Nature Communications
- Proteomic analysis of the response to cell cycle arrests in human myeloid leukemia cells
- (2015) Tony Ly et al. eLife
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
- (2014) Antonino Maria Spartà et al. CELL CYCLE
- CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
- (2014) Wenxiu Qi et al. Journal of Hematology & Oncology
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
- (2014) Katharine L. Sackton et al. NATURE
- The aurora kinases in cell cycle and leukemia
- (2014) B Goldenson et al. ONCOGENE
- PLK1expression and BI 2536 effects in childhood acute lymphoblastic leukemia
- (2014) J.C. Oliveira et al. PEDIATRIC BLOOD & CANCER
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
- (2013) Ivana Gojo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- NUP98 Fusion Oncoproteins Promote Aneuploidy by Attenuating the Mitotic Spindle Checkpoint
- (2013) V. Salsi et al. CANCER RESEARCH
- Catastrophic Nuclear Envelope Collapse in Cancer Cell Micronuclei
- (2013) Emily M. Hatch et al. CELL
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells
- (2013) S. A. Hartsink-Segers et al. HAEMATOLOGICA
- BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy
- (2013) D. Schnerch et al. HAEMATOLOGICA
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
- (2013) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
- (2013) Carlos Graux et al. LEUKEMIA RESEARCH
- The genomic landscape of hypodiploid acute lymphoblastic leukemia
- (2013) Linda Holmfeldt et al. NATURE GENETICS
- p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases
- (2013) M Marxer et al. ONCOGENE
- The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
- (2013) Alessia Casolaro et al. PLoS One
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
- (2012) Mike Dennis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation
- (2012) K. Hosokawa et al. HAEMATOLOGICA
- Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
- (2012) Kevin R. Kelly et al. INTERNATIONAL JOURNAL OF CANCER
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
- (2012) S A Hartsink-Segers et al. LEUKEMIA
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
- (2012) B. Valsasina et al. MOLECULAR CANCER THERAPEUTICS
- A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest
- (2012) Makoto T Hayashi et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
- (2011) B. Lowenberg et al. BLOOD
- Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis
- (2011) Darcy J.P. Bates et al. CANCER BIOLOGY & THERAPY
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development
- (2011) Philip J. Stephens et al. CELL
- Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis
- (2011) Seán Mac Fhearraigh et al. CELL CYCLE
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
- (2011) Mahesh Seetharam et al. LEUKEMIA RESEARCH
- Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction
- (2011) James D. Orth et al. MOLECULAR BIOLOGY OF THE CELL
- Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells
- (2010) Seiichi Okabe et al. ANNALS OF HEMATOLOGY
- Basal Dynamics of p53 Reveal Transcriptionally Attenuated Pulses in Cycling Cells
- (2010) Alexander Loewer et al. CELL
- Prolonged Prometaphase Blocks Daughter Cell Proliferation Despite Normal Completion of Mitosis
- (2010) Yumi Uetake et al. CURRENT BIOLOGY
- Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia
- (2010) R. Okamoto et al. HAEMATOLOGICA
- High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia
- (2010) Antonio R. Lucena-Araujo et al. LEUKEMIA RESEARCH
- ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
- (2010) G. C. Fletcher et al. MOLECULAR CANCER THERAPEUTICS
- Vinblastine Induces Acute, Cell Cycle Phase–Independent Apoptosis in Some Leukemias and Lymphomas and Can Induce Acute Apoptosis in Others when Mcl-1 Is Suppressed
- (2010) Bethany L. Salerni et al. MOLECULAR CANCER THERAPEUTICS
- AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
- (2009) A. Oke et al. CANCER RESEARCH
- Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML
- (2009) Kensuke Kojima et al. CANCER SCIENCE
- Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer
- (2009) W Brian Dalton et al. Future Oncology
- Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen
- (2009) John McLaughlin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies
- (2009) T Ikezoe et al. LEUKEMIA
- GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
- (2009) M. A. Hardwicke et al. MOLECULAR CANCER THERAPEUTICS
- Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation
- (2008) Jung Hwa Oh et al. APOPTOSIS
- Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs
- (2008) Karen E. Gascoigne et al. CANCER CELL
- Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
- (2008) E. Walsby et al. HAEMATOLOGICA
- Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review
- (2008) S. YEASMIN et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Genomic stability and tumour suppression by the APC/C cofactor Cdh1
- (2008) Irene García-Higuera et al. NATURE CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started